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Abstracts / Urological Science 26 (2015) S36eS49 S4710mm<IPP). All patients underwent surgical intervention with anterior
approach of prostatectomy and the continence component such as pubo-
prostatic ligament and arcus tendineus were preserved. Posterior recon-
struction of the rhabdomyosphincter was also performed. Continence was
deﬁned as no pad use or only one safety pad per day and assessed at 1, 3
and 12 months postoperatively. The correlation between the intravesical
prostatic protruding and postoperative continence was examed.
Results: The overall continence rate at 1, 3 and 12month was 69.2%, 91.33%
and 95.5%. Among the three groups, there is signiﬁcant difference in 1
month, 3 month and 12 month continence rate (IPP < 5mm: 82.5%, 96.3%,
97.7%; 5mm < IPP < 10mm: 61.9%, 89.4%, 94.4%; 10mm < IPP: 30%, 75.6%,
88.9%, p < 0.001). At one month, 415 patients achieved continence but 195
patients still incontinence and the length of IPP among the two groups
were 4.43 ± 3.74 mm and 8.69 ± 6.63mm, p < 0.001. Respectively, at the 3
month and 12 month, 548 and 573 patients achieved continence and the
IPP length among continence and incontinence groupwere 5.29 ± 4.56mm
vs. 10.50 ± 8.32mm and 5.55 ± 4.93 vs. 9.88 ± 8.37, there is also statistical
signiﬁcance.
Conclusions: To our result, the intravesical prostatic protrusion have
negative inﬂuence in continence of patients received robotic assisted
radical prostatectomy. The patient with less protruding prostate may
achieve early continence after operation and the postoperative inconti-
nence rate was markedly higher in patient with more protruding prostate.
MP5-2.
INHIBITION OF CELL GROWTH AND INDUCTION OF APOPTOSIS ON
HUMAN BLADDER CANCER CELLS WITH THE ANTIFUNGAL DRUG
MICONAZOLE
Sheau-Yun Yuan 1,3, Shian-Shiang Wang 1, Kan-Jen Tsai 2, Ming-Yuh
Shiau 3, Yen-Chuan Ou 1. 1Department of Surgery, Taichung Veterans
General Hospital; 2Department of Medical Technology, Chung Shan Medical
University, Taichung, Taiwan; 3Department of Nursing, HungKung
University, Taichung, Taiwan
Purpose: Miconazole (MIC) is an imidazole antifungal agent that is
commonly applied topically to the skin or mucous membranes to improve
fungal infections. Recent studies have demonstrated that MIC exhibits
anti-tumor effects on human colon cancers and leukemia. The aim of this
study was to determine the effects of MIC on the growth inhibition and
apoptosis of human bladder cancer cells.
Materials and methods: Human bladder cancer cell lines (T24 and TSGH-
8301) were used in this study. The T24 and TSGH-8301 cells were treated
with various concentrations (6, 12, 25, 50 and 100 mM) of MIC for 24 h each.
Cell viability was determined by MTT assay. The apoptosis mechanismwas
detected by sub-G1 population, DNA fragmentation and reactive oxygen
species (ROS) generation, and the mitochondrial membrane potentials
were evaluated by ﬂow cytometry. SDS-PAGE/Western blot assay was used
to detect apoptotic proteins (PARP, caspase-3/-8/-9), Bcl-2 family proteins
and cell-cycle-regulated proteins.
Results: The study showed that MIC elicited cytotoxic effects on human
T24 and TSGH-8301 bladder cancer cells in a dose- and time-dependent
manner with IC50 ~48.3 ± 0.35 mM and 47.8 ± 0.27 mM, respectively, as
determined by MTT assay. MIC increased the sub-G1 population, DNA
fragmentation formation, activation of caspase-3/-8/-9 and cleavage of
poly (ADPribose) polymerase (PARP), and provoked apoptosis in both
bladder cancer cell lines. Western blot analysis revealed increases of p21
and p27 protein levels, along with decreases of Cyclin E1, CDK2 and CDK4
expressed in MIC-treated T24 and TSGH-8301 cells, which is related to the
G0/G1 phase of the cell cycle. Meanwhile, there was an induced increase of
cleaved Bax proteins and a decrease of Bcl-2 proteins, up-regulation of the
DR5 death receptor and ROS generation subsequent to reduced mito-
chondrial membrane potential at higher concentrations (>50 mM) of MIC
for 24 h, in both the T24 and the TSGH-8301 bladder cancer cells.
Conclusions: These results indicate that MIC triggered apoptosis via G0/
G1 arrest, leading to the activation of the TRAIL death receptor, then
activation of caspase-3/-8/-9 and the ROS-dependent mitochondrial
pathway in human bladder cancer cells. This suggests that MIC may be a
potential anti-bladder cancer agent in humans.MP5-3.
SIGNIFICANCE OF HER2 EXPRESSION IN UPPER TRACT UROTHELIAL
CARCINOMA: A META-ANALYSIS
Chia-Horng Chen 1, Yuh-Shyan Tsai 2, Tzong-Shin Tzai 2. 1Department of
Urology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation,
Chia-yi County, Taiwan; 2Department of Urology, College of Medicine and
Hospital, National Cheng Kung University, Tainan, Taiwan
Purpose: Several studies explored the prognostic values of HER2 expres-
sion in upper tract urothelial carcinoma (UTUC), but the results remain not
consistent.
Materials andmethods: Using published evidence, we performed ameta-
analysis to examine its clinical values in patients with UTUC. Thirty-ﬁve
articles from 679 references related to EGFR family expression assessment
in UTUC were reviewed and there were 7 papers ﬁt for analyses. The es-
timates included the odds ratio (OR), distribution related to stage and
grade, hazard ratios (HR), and 95% conﬁdence intervals (CI) from survival
analyses of intravesical recurrence, progression and overall survival.
Results: The pooled results showed that HER2 expression is signiﬁcantly
associated with higher stage, but not with tumor grade in patients with
UTUC (OR, 2.05; 95% CI, 1.15-3.68; p ¼ 0.016 and OR, 4.73; 95% CI,
0.80e27.8; p ¼ 0.086, respectively). Also, the pooled survival analyses
demonstrated that HER2 expression yielded a worse recurrence-free sur-
vival in UTUC patients (HR, 4.32; 95% CI, 2.17e8.60; p < 0.0001). However,
there is lack of statistical signiﬁcance in term of progression-free survival
an overall survival (HR, 2.08; 95%CI, 0.46e9.32; p ¼ 0.339 and HR, 1.06;
95% CI, 0.48e2.37; p ¼ 0.879, respectively).
Conclusion: The relevant studies existed heterogeneous and were limited.
Our analysis suggests that HER2 expression plays an important role in
subsequent recurrence in the urinary bladder after primary treatment for
UTUC.
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Yuh-Shyan Tsai 1, Yeong-Chin Jou 2, Yen-Ping Tsai 1, Bin-Da Liu 3, Hung-In
Lin 4, Chia-Lin Wei 3, Syue-Yi Chen 5, Hsin-Tzu Tsai 1, Chien-Hui
Ou 1, Wen-Horng Yang 1, Tzong-Shin Tzai 1. 1Department of Urology,
National Cheng Kung University Hospital, College of Medicine, National
Cheng Kung University, Tainan, Taiwan; 2Department of Urology, Chia-Yi
Christian Hospital, Chia-Yi, Taiwan; 3Department of Electric Engineering,
College of Medicine and Hospital, National Cheng Kung University, Tainan,
Taiwan; 4Department of Chemical and Material Engineering, National
Kaohsiung University, Kaohsiung, Taiwan; 5Department of Medical
Research, Chia-Yi Christian Hospital, Chia-Yi, Taiwan
Purpose: Bladder cancer is a common human malignancy and exhibits a
life-long risk of disease recurrence and progression. It is continuing to
search some simple, innovative biomarker to monitor the disease status
in order to diminish the suffering during cystoscopic follow-up. The
metabolite of tryptophan after indoleamine 2,3-dioxygenase (IDO)
digestion, 3-Hydroxyanthranilic acid (3-HAA) is conventionally thought
to be a potential biomarker for bladder cancer occurrence. The aim to
study is to investigate the diagnostic potential of an integrated a 3-HAA-
based biosensor for urothelial carcinoma of the upper tract and urinary
bladder.
Materials and methods: Human urothelial cancer cell lines and human
urothelial carcinoma tissues as well as adjacent benign tissues were
available for exploring IDO expression, including western blotting and
immunohistochemical staining. Patients who received urological surgery
were enrolled for urine 3-HAA testing using an integrating biosensor for 3-
HAA. Some of urine specimens were investigated with high performance
liquid chromatography (HPLC) assay.
Results: From western blotting assays, eight human urothelial carcinoma
cell lines exhibited more IDO expression than the immortalized cell SV-
HUC. Both of urothelial carcinoma of urinary bladder and upper urinary
tract exhibited more IDO immunoreactivity than those of the adjacent
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There is a moderate correlation for urine 3-HAA measurement based on
between HPLC and the biosensor assays (r2¼ 0.47, p¼ 0.0033). Besides, the
3-HAA content within the cultured media of TCCSUP and BFTC905
measured with biosensors signiﬁcantly increased with incubation time
(p < 0.0001). Finally, Patients with urothelial carcinoma of bladder and
upper tract have higher urine 3-HAA levels than those without recurrence
or benign urological disease, such as BPH, or hernia (unpaired t-test,
p ¼ 0.028), except for urolithiasis.
Conclusion: The integrated biosensor exhibited a modest accuracy in
urine 3-HAA detection. Both of urothelial carcinoma of urinary bladder and
upper tract exhibited higher IDO expression and its metabolite 3-HAA in
urine.
MP5-5.
CERAMIDE PROMOTES TNF-a-INDUCED CELL DEATH VIA DECREASING
AKT ACTIVITY IN BLADDER CANCER CELL
Hsiao-Hsien Wang 1, Yu-Chi Tsou 2, Shye-Jye Tang 2. 1 Section of Urology,
Cheng-Hsin Rehabilitation Medical Center, Taipei, Taiwan; 2 Institute of
Bioscience and Biotechnology, National Taiwan Ocean University, Keelung,
Taiwan
Purpose: Bladder cancer, a malignant urinary system tumor, is in the ninth
position of the international cancer charts. The cancer shows a highly
recurrent rate that is around 50%~60%. Therefore, investigating a new
therapy to improve the curing rate of the cancer is important. Nowadays,
Bacillus- Calmette-Guerin (BCG) immune therapy is the most common
way for the treatment of bladder cancer. However, there are around 20 %
patients unable to get any beneﬁt from this, and the main mechanism of
the effect of BCG is still unclear. Since BCG treatment have reported, that
macrophages might be recruited into the bladder to induce cancer cell
death by the pro-inﬂammatory response, we further study the mechanism
of BCG. We used lipopolysaccharide to induce macrophage Raw264.7 for
the generation of condition medium (CM-LPS). Our results demonstrated
that CM-LPS might cause cell death via a caspase-dependent manner in
MBT2 bladder cancer cells. As compared with CM-LPS, TNF-a involved the
cell death. Moreover, TNF-a-induced AKT activation was found in MBT2
cell, implying that the activating AKT may have anti-apoptotic activity.
Since ceramide is generated after inﬂammation, we propose that ceramide
may increase TNF-a-induced cell death in bladder cancer.
Materials and methods: MBT-2 cell were treated with different concen-
trations of TNF-a, ceramide, and then the cell death were analyzed with
MTS analysis and Hoechst3334.2 staining for chromatin condensation. The
mechanisms of the cell death of TNF-a combining with ceramide were
investigated by using western blotting to detect AKT activation.
Results: In our study exhibits that TNF-a had slightly to induce MBT2 cell
death. Moreover, using western blot to analyze AKT expression in bladder
cell were exhibited that ceramide decrease AKT activation. In our study,
ceramide reduced AKT activity, promoted mitochondrial disruption and
dephosphorylated Bad, a BH3 containing pro-apoptotic protein. TNF-a
combining with ceramide exhibited chromatin condensation and DNA
fragmentation by Hochest33342 staining assay. Our ﬁndings suggest that
CM-LPS has the cytotoxic activity via ceramide and TNF-a to elicit cell
death in MBT2 cell.
Conclusions: In this study, we suggest that ceramide were promoted TNF-
a-induced cell death via decreasing AKT activity in bladder cancer cell.
These results are demonstrated that ceramide-mediated AKT inactivation
may play an important role in BCGeinduced cell death in MBT2 bladder
cancer cells. Our ﬁndings suggest that improvement of bladder cancer
therapy will be able to decrease the activation of AKT.
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TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA: CASE
SERIES STUDY IN SINGLE HOSPITAL EXPERIENCE
Tzu-Hsiang Wu 1, Yi-Chia Lin 1,2, Te-Fu Tsai 1,2, Guang-Dar Juang 1,2, Chung-
Hsin Yeh 1,2, Yi-Hung Cheng 1,2, Kuang-Yu Chuo 1, Hung-En Chen 1, Thomas
I.S. Hwang 1,2. 1Division of Urology, Department of Surgery, Shin-Kong WHS
Memorial Hospital, Taipei, Taiwan, ROC; 2Department of Urology, Fu Jen
Catholic University School of Medicine, Taipei, Taiwan, ROCPurpose: Treatment for metastatic renal cell carcinoma (mRCC) has
recently focused on targeted therapy including tyrosine kinase inhibitors
andmTOR inhibitors. Molecular-targeted therapies have been proved to be
effective treatment options. We herein report the outcomes of targeted
therapy for mRCC in our institution.
Materials and methods: From 2010 to 2015, 15 mRCC patients were
identiﬁed in our institute under targeted therapy with a diagnosis of
mRCC. Three targeted agents, namely temsirolimus, sunitinib, and ever-
olimus, were given for patient according to the clinical condition. Sunitinib
and Temsirolimus were served as ﬁrst-line treatment and Everolimus was
the secondeline treatment. Demographics, the interval between diagnosis
of metastasis and targeted therapy, the duration of targeted therapy, side
effects and complications after treatment were collected with a retro-
spective medical record review. Response rate were analyzed according to
RECIST criteria.
Results: Among the 15 patients, 9 were male and 6 were female. The mean
age was 70.3 (35-88) years old. Lung metastasis was noted in 80% (12/15)
of the patient, and other sites of metastasis were also noted, including
lymphnodes, liver, bone and adrenal gland. The mean interval between
diagnosis of metastasis and targeted therapy is 27.5 (1e78) days. The mean
duration of targeted therapy is 268.5 days with temsirolimus, 397.8 days
with sunitinib and 360.3 days with everolimus. The most common side
effect noted in targeted therapy is anemia (100%) in temsirolimus group,
hand-foot mouth syndrome (61.5%) and hypertension (61.5%) in sunitinib
group, and cough (50%) (without radiologic sign of interstitial pneumo-
nitis) in everolimus group. There were 2 patients (2/4) with disease
regression and 2 (2/4) with stationary disease under everolimus usage,
compared with 2 patients (2/12) with disease regression, 5 patients (5/12)
with progression disease and 5 patients in stationary status under suni-
tinib usage. One patient with temsirolimus usage was in disease pro-
gression, and the other was in stationary status.
Conclusion: Targeted therapy prolonged the life of mRCC patients with
tolerable outcome. In our series, the response rate of Everolimus is higher
than expected.
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NEPHRON-SPARING MANAGEMENT (DISTAL URETERECTOMY WITH
REIMPLANTATION OF URETER) FOR CARCINOMA OF DISTAL URETER:
A SINGLE CENTER EXPERIENCE
Yen-Hsi Lee 1,2, Yu-Chi Chen 1, Victor C. Lin 1, Tsan-Jung Yu 1, Hua-Pin
Wang 1, Chao-Yang Jiang 1, Hung-Yu Lin 1, Kelvin Lu 1, Ching-Yu
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Purpose: Radical nephroureterectomy (NU) with bladder-cuff excision has
been the traditional treatment for UTUC because of its high rate of recur-
rence. However, given the morbidity of nephrectomy and the risk of
developing chronic kidney disease (CKD) or dialysis-dependent renal
failure, a nephron-sparing approach may be preferable in selected
patients.
Materials and methods: We retrospectively analyzed 19 patients from
March 2006 to December 2014 at single center in Southern Taiwan who
underwent distal ureterectomy with reimplantation of ureter and
conﬁrmed to be ureter malignancy (urothelial carcinoma n ¼ 18, squa-
mous cell carcinoma n ¼ 1) on ﬁnal pathology. Outcome measures were
recurrence or distant metastasis, renal function preservation, time to
recurrence and overall survival.
Results: Total 19 patients, 13males, 6 females, andmean age are 69.3 years
old. There are no local recurrence, 9 bladder recurrence (47.4%), 3 distant
metastasis (15.8%), and 2 progression to radical nephroureterectomy
(10.5%). Pathological staging: Tis n¼ 1, Ta n¼ 3, T1 n¼ 2, T2 n¼ 6, T3 n¼ 5.
Low grade n ¼ 3, high grade n ¼ 12. Mean time to recurrence was 12.4
(3e24) months, and mean follow up time was 28.1 (1e90) months. Overall
survival rate is 73.7% (14/19), among them, 4 lost follow up, 1 expired.
Mean pre-op creatinine was 1.61 mg/dl, 1 yr post operation creatinine was
1.56mg/dl.
Conclusion: Distal ureterectomy with reimplantation surgery in our
experience is a feasible option for distal ureter tumor in selected patients
(chronic kidney disease, solitary kidney). Favorable post-operative
